Vir Biotechnology, Inc. completed a $100 million acquisition of a license for three clinical-stage T-cell engagers and a masking platform from Sanofi, with potential future payments totaling up to $1.811 billion based on milestones and royalties. Additionally, Jason O'Byrne was appointed as CFO with a base salary of $530,000 and significant equity awards.